DE69835165D1 - Pharmazeutische zusammensetzung enthaltend glyzin als stabilisator - Google Patents

Pharmazeutische zusammensetzung enthaltend glyzin als stabilisator

Info

Publication number
DE69835165D1
DE69835165D1 DE69835165T DE69835165T DE69835165D1 DE 69835165 D1 DE69835165 D1 DE 69835165D1 DE 69835165 T DE69835165 T DE 69835165T DE 69835165 T DE69835165 T DE 69835165T DE 69835165 D1 DE69835165 D1 DE 69835165D1
Authority
DE
Germany
Prior art keywords
stabilizer
pharmaceutical composition
composition containing
hours
containing glycine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69835165T
Other languages
English (en)
Other versions
DE69835165T2 (de
Inventor
James Mcshane
Ray Wood
Sumio Watanabe
Kiyoshi Iwamoto
Katsumi Onai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Application granted granted Critical
Publication of DE69835165D1 publication Critical patent/DE69835165D1/de
Publication of DE69835165T2 publication Critical patent/DE69835165T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE69835165T 1997-10-14 1998-09-14 Pharmazeutische Formulierung, die Glycin als Stabilisator umfasst Expired - Fee Related DE69835165T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6208997P 1997-10-14 1997-10-14
US62089 1997-10-14
PCT/US1998/021972 WO1999018959A1 (en) 1997-10-14 1998-09-14 Pharmaceutical formulation comprising glycine as a stabilizer

Publications (2)

Publication Number Publication Date
DE69835165D1 true DE69835165D1 (de) 2006-08-17
DE69835165T2 DE69835165T2 (de) 2007-06-06

Family

ID=22040157

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69835165T Expired - Fee Related DE69835165T2 (de) 1997-10-14 1998-09-14 Pharmazeutische Formulierung, die Glycin als Stabilisator umfasst

Country Status (11)

Country Link
EP (1) EP1039905B1 (de)
JP (1) JP3459407B2 (de)
AT (1) ATE332133T1 (de)
AU (1) AU1361399A (de)
CA (1) CA2308143A1 (de)
CY (1) CY1106181T1 (de)
DE (1) DE69835165T2 (de)
DK (1) DK1039905T3 (de)
ES (1) ES2268800T3 (de)
PT (1) PT1039905E (de)
WO (1) WO1999018959A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2419067C (en) * 2000-08-18 2008-12-23 Takeda Chemical Industries, Ltd. Injectable composition comprising benzimidazole compound and strong alkali
MY137726A (en) 2000-11-22 2009-03-31 Nycomed Gmbh Freeze-dried pantoprazole preparation and pantoprazole injection
WO2003082854A1 (fr) * 2002-03-29 2003-10-09 Zeria Pharmaceutical Co., Ltd. Derives 1-n-aminobenzimidazole
WO2005016225A2 (en) * 2003-08-18 2005-02-24 Bakulesh Mafatlal Khamar Stable pharmaceutical composition of rabeprazole
DE102004007854A1 (de) * 2004-02-17 2005-09-01 Hexal Ag Stabile, wässrige Formulierung für Benzimidazole
CN104840431B (zh) * 2014-02-13 2017-09-08 长春海悦药业股份有限公司 一种含有伏立康唑的药物组合物
CN112807282A (zh) * 2021-01-13 2021-05-18 海南葫芦娃药业集团股份有限公司 一种奥美拉唑钠冻干粉针剂及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5610110A (en) * 1979-07-06 1981-02-02 Green Cross Corp:The Acetyl salicylate salt preparation for injection
JPS5665816A (en) * 1979-11-01 1981-06-03 Green Cross Corp:The Acetylsalicylate pharmaceutical for injection
EP0082481B2 (de) * 1981-12-23 1990-09-12 Schering Corporation Stabilisierte alpha-Interferon-Zusammensetzungen und ihre Herstellung
FI90544C (fi) * 1986-11-13 1994-02-25 Eisai Co Ltd Menetelmä lääkeaineina käyttökelpoisten 2-pyridin-2-yyli-metyylitio- ja sulfinyyli-1H-bensimidatsolijohdannaisten valmistamiseksi
JPH0594225A (ja) * 1991-09-30 1993-04-16 Toshiba Corp セキユリテイ機能を内蔵したパーソナルコンピユータ
JPH05194225A (ja) * 1991-11-07 1993-08-03 Yoshitomi Pharmaceut Ind Ltd 安定化された抗潰瘍剤含有製剤
US6270757B1 (en) * 1994-04-21 2001-08-07 Genetics Institute, Inc. Formulations for IL-11

Also Published As

Publication number Publication date
DE69835165T2 (de) 2007-06-06
PT1039905E (pt) 2006-11-30
EP1039905A1 (de) 2000-10-04
ES2268800T3 (es) 2007-03-16
AU1361399A (en) 1999-05-03
CA2308143A1 (en) 1999-04-22
ATE332133T1 (de) 2006-07-15
WO1999018959A1 (en) 1999-04-22
CY1106181T1 (el) 2011-06-08
DK1039905T3 (da) 2006-11-06
EP1039905B1 (de) 2006-07-05
JP3459407B2 (ja) 2003-10-20
WO1999018959A9 (en) 1999-08-05
JP2001519390A (ja) 2001-10-23

Similar Documents

Publication Publication Date Title
PL319603A1 (en) Stable aqueous alpha interferon preparations
NO971889D0 (no) Forbindelser og sammensetninger for levering av aktive midler
KR950703987A (ko) G-csf의 안정한 동결건조된 약제학적 제제(stable lyophilized pharma ceutical preparations g-csf)
KR920019371A (ko) 안정화된 인자 ⅷ 제제
CA2478621A1 (en) Botulinum toxin pharmaceutical compositions
MY120984A (en) Activated protein c formulations
FI953442A (fi) Gonadotropiinia sisältäviä pakastekuivattuja pallosia
NO883926L (no) Fremgangsmaate for fremstilling av stabilisert humanproteinpreparat.
CA2113995A1 (en) Use of gentisic acid or gentisyl alcohol for stabilising radiolabeled peptides and proteins
CA2341568A1 (en) Stabilized pharmaceutical composition in lyophilized form
CA2226548A1 (en) Lyophilized hepatocyte growth factor preparations
DE60034445D1 (de) Gefriergetrocknete hgf-präparationen
CY1106181T1 (el) Φαρμακευτικος σχηματισμος ο οποιος πepιλαμβανει γλυκινη σαν ενα σταθepοποιητη
IT1314185B1 (it) Composizione farmaceutica per somministrazione di sostanze attivescarsamente solubili in mezzi acquosi
ATE345139T1 (de) Karzinostatische wirkstoffe
NO911788D0 (no) Galeniske vandige preparater av erytropoietin.
SE9502927D0 (sv) Solution containing IGF-I
Walker et al. Preparation of allosteric ribonuclease
DK1204676T3 (da) Streptograminderivater, deres fremstilling samt præparater indeholdende disse derivater
JPS6219531A (ja) 安定なヒト型アンギオテンシン製剤

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: EISAI R&D MANAGEMENT CO., LTD., TOKIO, JP

8339 Ceased/non-payment of the annual fee